The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST).
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; Kolltan Pharmaceuticals
Consulting or Advisory Role - ARIAD; AstraZeneca; Bayer; Blueprint Medicines; Daiichi Sankyo; EMD Serono; G1 Therapeutics; GlaxoSmithKline; Janssen Oncology; Lilly; Novartis; Pfizer; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Bayer (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Novartis (Inst)
 
Peter Reichardt
Honoraria - Amgen; Bayer; GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Amgen; ARIAD; Bayer; GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Research Funding - Novartis (Inst)
 
Yoon-Koo Kang
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Bayer; Novartis; Roche/Genentech
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pharmamar; PharmaMar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Novartis; PharmaMar; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst)
 
Heikki Joensuu
Stock and Other Ownership Interests - Orion
Honoraria - ARIAD; Blueprint Medicines
Consulting or Advisory Role - ARIAD; Blueprint Medicines
 
Klaus Schaefer
Employment - Bayer
Stock and Other Ownership Interests - Bayer
Honoraria - Bayer
Travel, Accommodations, Expenses - Bayer
 
Andrea Wagner
Employment - Bayer
 
Paolo Giovanni Casali
Honoraria - Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Amgen/Dompé; ARIAD/Merck; Bayer; Blueprint Medicines; GlaxoSmithKline; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar
Research Funding - Amgen/Dompé (Inst); Bayer (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MolMed (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Novartis; PharmaMar
 
Christian Kappeler
Employment - Bayer
Stock and Other Ownership Interests - Bayer